US could soon approve MDMA therapy — opening an era of psychedelic medicine

For Rick Doblin, 2023 could be a landmark year: the year that the US government decides whether it will allow the use of hallucinogenic drugs to treat mental illness.

Doblin, who is based in Belmont, Massachusetts, is the founder and president of the non-profit organization Multidisciplinary Association for Psychedelic Studies (MAPS). He has spent nearly 40 years researching whether the experience produced by the psychedelic drug MDMA — also called ecstasy or molly — can help people with post-traumatic stress disorder (PTSD). In 2021, MAPS’s phase III clinical trial of 90 people with PTSD found that those who received MDMA coupled with psychotherapy were twice as likely to recover from the condition as were those who received psychotherapy with a placebo1 (see ‘Response to MDMA therapy’).

Keep reading

Author: HP McLovincraft

Seeker of rabbit holes. Pessimist. Libertine. Contrarian. Your huckleberry. Possibly true tales of sanity-blasting horror also known as abject reality. Prepare yourself. Veteran of a thousand psychic wars. I have seen the fnords. Deplatformed on Tumblr and Twitter.

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: